Table 1.
Bevacizumab in ES-SCLC.
| Author | Regimen | Patients | ORR (%) | Median TTP/PFS (months) | Median OS (months) | 1-year OS (%) | Grade 3-4 toxicity (%) |
|---|---|---|---|---|---|---|---|
| Spigel DR et al., LUN90 | CaIB | 51 | 84 | 9.1 | 12.1 | 51 | Thrombocytopenia (53), fatigue (31), dehydration (26), diarrhea (21), hyperglycemia (21), pain (21) |
| Horn L et al., E3501 | CEB | 63 | 63.5 | 4.7 | 10.9 | 38.1 | Neutropenia (57.8), thrombocytopenia (14.1), fatigue (14.1) |
| Ready NE et al., CALGB30306 | CIB | 72 | 75 | 7.0 | 11.6 | 43.8 | Neutropenia (25), diarrhea (16), dehydration (12), thrombocytopenia (10), fatigue (10), nausea (10) |
| Spigel DA et al., SALUTE | Ca/CEB vs Ca/CEP | 102 | 58 vs 48 | 5.5 vs 4.4 | 9.4 vs 10.9 | – | Neutropenia (35), pneumonia (5.9), dyspnea (3.9), thrombocytopenia (4), hypertension (5.9) |
| Pujol JL et al., IFCT-0802 | CT vs CT + B | 147 | 89.2 vs 91.9, p=1.00 | 5.5 vs 5.3, p=0.82 | 13.3 vs 11.1, p=0.80 | – | Hypertension (40), thrombosis (11) |
| Tiseo M et al., FARM6PMFJM | CEB vs CEP | 204 | 58.4 vs 55.3, p=0.657 | 6.7 vs 5.7, p=0.03 | 9.8 vs 8.9, p=0.11 | 37 vs 25 | Neutropenia (46.3), fatigue (8.4), hypertension (6.3), thrombosis (5.3) |
Ca, carboplatin; C, cisplatin; I, irinotecan; E, etoposide; B, bevacizumab; P, placebo; CT, chemotherapy chosen by each center, cisplatin etoposide or cisplatin-cyclophosphamide-epidoxorubicin-etoposide.